Skip to main content
Signal8

Dogwood Therapeutics Appoints Iain Dukes, Venture Partner at OrbiMed, as Chair of Scientific Advisory Board

$DWTXPress releaseJun 30, 2026, 8:45 AM ETRead the release

Dogwood Therapeutics appointed Iain Dukes, a Venture Partner at OrbiMed and former Merck and Amgen executive, as Chair of its newly formed Scientific Advisory Board. Dr. Dukes will provide strategic guidance on the company's pipeline, leveraging his deep experience in ion channel therapeutics relevant to the lead asset Halneuron.

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.